drugset / Trial / NCT07282600
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Timeline
- Start
- 2025-12-15
- Primary completion
- 2028-01
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eloralintide | Protein / enzyme biologic | — | Subcutaneous |